Dean Diagnostic Technology Group Co., Ltd., with the mission of "Let Chinese people share health equally", is committed to providing integrated medical diagnosis solutions based on third-party diagnostic services. The company was founded in 1996 and listed in July 2011 (stock code: 300244). At present, it has 42 chain medical laboratories nationwide, serving more than 20000 medical institutions nationwide. The company actively laid out the health diagnosis and treatment industry chain, covering medical diagnosis services, diagnostic technology research and development, diagnostic product production and marketing, CRO, judicial expertise, health management, cold chain logistics and other fields.

The company focuses on building four major departments of cancer, infection, chronic disease and maternal and child genetics, as well as two major technology platforms of genomics, protein and metabonomics. In the fields of gene sequencing, PCR, tandem mass spectrometry, nucleic acid mass spectrometry, pathological diagnosis, etc., we have many technologies and products with independent intellectual property rights and patents by virtue of our R&D advantages and product production capacity. The company was approved as one of the first batch of national tumor diagnosis and treatment project high-throughput gene sequencing technology pilot units, the first batch of national gene detection technology clinical application demonstration center, and the national third-party high-performance medical diagnosis and treatment equipment application demonstration center.